通过托法西提尼布剂量逐渐减小,维持脱发区域的治疗反应:单中心回顾性研究
Jundong Huang1, Jia Jian1, Min Li1
1Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key Laboratory of Aging Biology, Changsha, China.
Journal of the American Academy of Dermatology
|December 10, 2025
概括
一个以患者为中心的托法西提尼布逐渐减少的策略有效地保持了对白发性 (AA) 反应者的疾病控制. 这种方法在不影响疗效的情况下降低了药物暴露,为减少治疗负担提供了潜在的途径.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 雅努斯酶 (JAK) 抑制剂已经改变了脱发区 (AA) 的管理.
- 关于通过剂量逐渐减少策略维持疾病控制的数据有限.
研究的目的:
- 在完全缓解的AA患者中评估以患者为中心的托法西提尼布剂量方案.
- 评估AA患者逐渐减少托法西提尼布的可行性和有效性.
主要方法:
- 对46名AA患者进行了回顾性观察队列研究,这些患者在托法西提尼布的治疗中实现了完全的头发再生.
- 实施了结构化的剂量逐渐减少,结果在48周内进行评估.
- 监测了临床结果,药物暴露和不良事件.
主要成果:
- 观察到持续控制疾病的高率 (95.7%在24周,93.5%在48周).
- 在80.4%的患者中,成功降低了剂量,显著减少了累积药物暴露.
- 治疗效益的损失是罕见的,并且没有确定逐渐减缓成功的显著预测因素.
结论:
- 一个以患者为中心的tofacitinib逐渐减少的策略是可行的AA响应者.
- 降低剂量可能会降低治疗负担,而不会影响疗效.
- 需要进一步研究更大的样本大小和更长的随访时间.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
408
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
408
Therapeutic Drug Monitoring: Affecting Factors
175
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
175
Desensitization and Tachyphylaxis
2.9K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.9K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
459
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
445
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


